title: [Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)].
authors.forename: Ralf
authors.initials: R
authors.lastname: Göddertz
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000191:economics; D000241:Adenosine / Q000031:analogs & derivatives / Q000191:economics; D000077144:Clopidogrel; D017046:Cost Savings / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000191:economics*; D016527:Drug Costs / Q000639:trends*; D004345:Drug Industry / Q000191:economics*; D016568:Drugs, Generic / Q000191:economics*; D005544:Forecasting; D005858:Germany; D006801:Humans; D009313:National Health Programs / Q000191:economics*; D010330:Patents as Topic; D010879:Piperazines / Q000191:economics; D010975:Platelet Aggregation Inhibitors / Q000191:economics; D000068799:Prasugrel Hydrochloride; D013876:Thiophenes / Q000191:economics; D000077486:Ticagrelor; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000191:economics; D016896:Treatment Outcome
chemical_list: D016568:Drugs, Generic; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine